Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,605.60GBp
9:05pm IST
Change (% chg)

12.60 (+0.79%)
Prev Close
1,593.00
Open
1,587.40
Day's High
1,608.60
Day's Low
1,581.00
Volume
5,271,421
Avg. Vol
7,358,756
52-wk High
1,648.80
52-wk Low
1,408.80

Select another date:

Thu, Jun 20 2019

Photo

GSK offers concessions to address EU concerns over Pfizer deal

BRUSSELS GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

GSK offers concessions to address EU concerns over Pfizer deal

BRUSSELS, June 20 GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

GSK kicks off sale of $1.2 billion consumer health drugs: sources

LONDON GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.

GSK kicks off sale of $1.2 billion consumer health drugs: sources

LONDON GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.

GSK kicks off sale of $1.2 bln consumer health drugs -sources

LONDON, June 19 GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.

GSK pharma head flags need for speed in high-pressure drug market

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

GSK pharma head flags need for speed in high-pressure drug market

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

GSK pharma head flags need for speed in high-pressure drug market

LONDON, June 17 Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

Germany's Stada buys six of GSK's consumer brands, eyes further deals

FRANKFURT, June 7 Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.

GSK's Nucala wins European panel thumbs-up for self-administration

June 4 GlaxoSmithKline said on Tuesday it had won marketing approval from a European Medicines Agency (EMA) panel for its Nucala drug to be self-administered to treat severe asthma.

Select another date: